Companies › Jiangsu Aosaikang Pharmaceutical
5 active drug programs in 7 registered trials: 3 Phase 1, 2 Phase 3, 2 Phase 2; Oncology, Infectious disease, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASKC202 EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Locally Advanced or Metastatic NSCLC; Advanced Solid Tumor | Dec 2026 |
| ASK0912 for Injection Monobactam antibiotic | – | Phase 2 | Ventilator-associated Bacterial Pneumonia (VABP) | Oct 2027 |
| ASKC200 | – | Phase 2 | Osteoarthritis (OA) of the Knee | – |
| ASK120067 (Limertinib) EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| ASKB589 Injection | – | Phase 1 | Malignant Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04632108 | ASKB589 Injection | Phase 1 | Malignant Solid Tumor | Oncology | Oct 2025 |
| NCT07742852 | ASKC200 | Phase 2 | Osteoarthritis (OA) of the Knee | Immunology | Apr 2026 |
| NCT05306132 | ASKC202 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05306132 | ASK120067 (Limertinib) | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07759934 | ASK0912 for Injection | Phase 2 | Ventilator-associated Bacterial Pneumonia (VABP) | Infectious disease | Oct 2027 |
| NCT07109531 | ASKC202 | Phase 3 | Locally Advanced or Metastatic NSCLC | Oncology | Oct 2027 |
| NCT07109531 | ASKC202 | Phase 3 | Locally Advanced or Metastatic NSCLC | Oncology | Oct 2027 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Nanjing Sanhome Pharmaceutical Jiangsu Alphamab Biopharmaceuticals HC Biopharma Wayshine Biopharm ArriVent BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.